But what of those diseases in which the genetic contribution, although unequivocal, cannot be confidently ascribed to mutations at a single locus. Among nervous system disorders, psychiatric diseases and the epilepsies come into this category. Can the approaches which have been so spectacularly successful in Mendelian diseases be applied to complex genetic diseases? The epilepsies are merely a particular example of this general problem which has been exercising molecular geneticists for several years in respect of, for example, heart disease and diabetes mellitus. The suggestion that it might be possible to map epilepsy genes was first made several years ago. '2 It is first necessary to define what is meant by epilepsy. The term itself encompasses as diverse a group of diseases as does the term anaemia. The evidence for a genetic contribution to specific epilepsy phenotypes will be briefly described with particular reference to the unavoidable uncertainties concerning genetic mechanisms. Strategies for linkage analysis of complex genetic diseases will be considered with particular reference to their application to the epilepsies.
Epilepsy and its causes
Epilepsy is, of course, no more a disease entity than anaemia. The analogy with anaemia is instructive in several ways, but even the most partisan haematologist will admit that the human brain is substantially more complex than the human red cell. The causes of epilepsy range, as do those of anaemia, from the purely environmental (for example, post-traumatic) to the apparently purely genetic (for example, as a component of the phenotype in tuberous sclerosis). Genetic influences on this aspect of brain function may be quite indirect. The genes do not necessarily code for proteins synthesised in the central nervous system: the seizures of hyperphenylalaninaemia owing to mutations in the phenylalanine hydroxylase gene and of hyperammonaemia owing to mutations in the gene for ornithine transcarbamylase would be examples of this. It is not, however, such genes as these which are at issue here. Rather, we seek the equivalent of the genetic haemoglobinopathies.
Unfortunately ( Nevertheless, studies of several epilepsy phenotypes have provided evidence for a genetic component in their aetiology. These include 'grand mal' epilepsy, 'absence' epilepsy, juvenile myoclonic epilepsy of Janz, benign rolandic epilepsy with centrotemporal spikes, and febrile convulsions. In addition, a genetic contribution to the aetiology of several EEG patterns, including generalised spike waves, focal spikes, and the photoconvulsive response, has been identified.6 7 Most commonly, the conclusion has been that the mechanism of inheritance is 'multifactorial', although not Lastly, the mitochondrial genome can be regarded as a collection of candidate epilepsy genes. It is not difficult to envisage how disruption of cellular energy metabolism may initiate seizure activity, and myoclonic seizures are a component of the phenotype in several diseases in which abnormalities of the mitochondrial genome have been documented. Various mechanisms exist which might confine the phenotypic effects of mutations in this genome to the central nervous system.
Of course, the existence of a host of 'candidate' genes, unimagined and uncloned, specifying complex functions such as those concerned with the development of neuronal interconnections can only be surmised. It can be anticipated that the next few years will see no shortage of gene cloning activity in relation to the human central nervous system: some of those genes may turn out to be involved in the epilepsies.
Linkage analysis using 'random' markers The epilepsies, in common with a number of important diseases, display most of those characteristics which render them unsuitable for linkage analysis.
Subjects with the mutant genotype may fail to manifest the disease (incomplete penetrance) and those of normal genotype may apparently display the mutant phenotype owing to non-genetic causes (phenocopies). Non-allelic genetic heterogeneity may be present: mutations at several different loci may result in apparently identical clinical conditions. Lastly, the disease trait may result from genetic interactions between alleles at several loci, but at least one locus is essential for development of the disease. The extreme situation of polygenic inheritance, in which alleles at numerous loci interact in an additive way to determine susceptibility, is the only complexity which appears to render attempts at linkage analysis impractical on formal mathematical grounds. The epilepsies do, however, have one advantage. They are not rare.
Confronted by these difficulties, how can the chance of success be maximised and the chance of error be minimised ?42 When penetrance is incomplete, the genotype of an unaffected descendant of an affected subject is always in doubt. The safest approach, if resources are sufficient, is not to include data on unaffected subjects. The potential problem of misdiagnosing unaffected persons as affected is another risk: any subject for whom the diagnosis is in doubt is best designated 'phenotype unknown' and excluded from the analysis.
There is no certain way of circumventing the potential problem of non-allelic genetic heterogeneity: a disease may be clinically homogeneous, even though it arises from mutations at different loci, and vice versa. The risk can be reduced but not eliminated, and it should be remembered that linkage will be obscured by quite a modest degree of heterogeneity. The clinical phenotype may be subdivided, in the hope that clinical features will distinguish the different genetic forms. The study may be confined to a single large pedigree, or to a single geographical region with a relatively isolated population.
Lastly, the method of 'simultaneous search' makes use of the availability of a complete RFLP linkage map of the human genome. If after screening RFLPs spanning the entire genome no single genetic interval shows tight linkage, two or more intervals are examined simultaneously for linkage to the disease. A set of loci accounting together for segregation in all the families is more easily recognised than a single locus accounting for segregation in a fraction of them.
The difficulties encountered in mapping loci which interact to produce a trait correspond to those arising from phenocopies and reduced penetrance. If the allele frequency at a component locus is high (>10%) parental homozygosity may occur. An affected child may inherit either chromosome from a homozygous parent, and linkage to the locus will not be apparent in that family. (The risk of parental homozygosity may be reduced by avoiding families with a high proportion of affected sibs.) The genotypes of unaffected children cannot be used as evidence against linkage to a particular locus: the disease causing allele may have been inherited, but without the required alleles at other loci the disease is not expressed. This equates to one locus causing the disease with low penetrance.
It is clear that a number of approaches can be used in the application of linkage analysis to the epilepsies. An important factor is that the data can be analysed and reanalysed under any number of different assumptions, and different mixtures of assumptions concerning mode of inheritance and genetic homogeneity or heterogeneity. The jigsaw piece can be tried in all orientations. Provided the family resources are large, and pedigrees in which the clinical information is potentially unreliable are ruthlessly excluded, reliable information should emerge.
Two further approaches are worth considering. The affected sib pair method of linkage analysis detects departures from independent segregation of disease and marker phenotypes and requires no specification of the mode of inheritance. This method has recently been generalised to 45 46 BFNC is, of course, the most favourable epilepsy syndrome for linkage analysis, with a segregation pattern indicating an autosomal dominant mode of inheritance, and presents none of the difficulties discussed above. In a single, large pedigree two polymorphic DNA marker loci on chromosome 20 were found to be tightly linked to the disease locus, giving maximum lod scores of 3-12 (0=0 003, for RMR6 detecting D20S20) and 2-87 (0=0 039, for CMM6 detecting D20S19). Multipoint analysis of the disease locus and both these loci gave a lod score of 5-64 with no obligate recombinants.
Juvenile myoclonic epilepsy (JME) is far more representative of the problems pertaining to mapping epilepsy syndromes. This is a non-progressive form of generalised epilepsy distinguished by a characteristic age of onset (9 to 20 years) and myoclonic jerks which occur most often on awakening. Grand mal generalised tonic-clonic seizures occur in 95% of patients, and about 30% have absence seizures. In one study, all untreated patients had an interictal EEG trait consisting of bilaterally symmetrical diffuse 4 to 6 Hz multispike and wave complexes. Ten per cent also had diffuse 3 Hz spike-wave complexes. Family members may show the same EEG abnormalities.
Linkage of JME to the HLA and Bf loci on human chromosome 6 has been found. Thirty-four, mostly nuclear, families were studied. Anyone with any form of generalised epilepsy or a positive generalised EEG trait was regarded as 'affected', and linkage analysis was carried out assuming either dominant or recessive inheritance and a range of penetrance values. Significant positive lod scores (>3-0) were obtained assuming either model at high penetrance values. Non-JME forms of epilepsy were present in four families. When these cases were reclassified as 'unaffected', the lod score increased under the assumption of a fully penetrant recessive. If these results are confirmed they will support hopes that linked loci can be found in epilepsy phenotypes displaying complex inheritance patterns.
Conclusions
The evidence that 'epilepsy genes' exist is strong. Familial segregation of human epilepsies provides good support for a genetic contribution to aetiology in several epilepsy syndromes, and present knowledge of the pathophysiology of seizures indicates that genes control functions related to neuronal synchrony. It is very reasonable to suppose that mutant alleles at specific loci manifested by liability to seizures occur in the human population.
Can these genes now be identified? There is no doubt that the molecular genetic techniques exist to examine the potential role of any 'cloned' candidate genes in the aetiology of seizures. It can be anticipated that a significant minority of the many thousands of genes expressed in human brain tissue will be cloned in the foreseeable future. Some of them may be the site of the disease mutations.
Mapping the disease loci through linkage to DNA markers on a 'random' basis is a more contentious issue. It is undeniable that the results of segregation analysis of some human epilepsies have been compatible with mechanisms of inheritance which are not at present amenable to linkage analysis. However, the evidence often does not allow other mechanisms to be conclusively excluded, and some of these, such as segregation of a single major locus, may yield to such an approach. It is not therefore possible to know in advance that a random search of the genome will prove futile, any more than it was possible to know in advance whether linkage studies in autosomal recessive disorders such as cystic fibrosis would be confounded by heterogeneity. What is now available is an experimental method for testing alternative hypotheses concerning inheritance; demonstration of linkage does more than map the gene locus.
The experiment is of course a daunting one. It requires the assembly of a very large resource of carefully documented families, genotyping of thousands of subjects at hundreds of loci, and complex computer assisted linkage analysis based on a wide range of different assumptions concerning mechanisms of inheritance and phenotypic classifications.
A European collaboration to achieve this is under way.
There is no guarantee of success, but the potential rewards are immense. The major benefits of the 'new genetics' are surely most likely to emerge in such common, non-lethal conditions. Some order may be imposed on a confused and confusing collection of clinical entities, and new, rapid, and accurate diagnostic methods will emerge. DNA analysis may not render EEGs obsolete, but it may one day be just as much a 'routine' investigation in a patient with epilepsy. Finally, there is a real possibility that new pharmacological tools will emerge based on the molecular pathological understanding of these common and disabling diseases.
